Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis

Liver Transplantation

Volumn 22, Issue 3, 2016, Pages 281-286

  Modi, Apurva A ^a   Nazario, Hector ^b   Trotter, James F ^a   Gautam, Manjushree ^a   Weinstein, Jeffrey ^b   Mantry, Parvez ^b   Barnes, Maisha ^b   Habib, Adil ^b   McAfee, Jean ^a   Teachenor, Olga ^b   Tujague, Lauren ^b   Gonzalez, Stevan ^a  

^a Liver Consultants of Texas   (United States)

^b METHODIST DALLAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BILIRUBIN; INTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; ANTIVIRUS AGENT;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD TRANSFUSION; BODY MASS; BRAIN DISEASE; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DECOMPENSATED HEPATITIS C GENOTYPE 1 LIVER CIRRHOSIS; DECOMPENSATED LIVER CIRRHOSIS; DISEASE CLASSIFICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG THERAPY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; GENE MUTATION; HEADACHE; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 1A; HEPATITIS C VIRUS GENOTYPE 1B; HUMAN; HYPERVOLEMIA; HYPOKALEMIA; INSOMNIA; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; MONOTHERAPY; NAUSEA; PANCREATITIS; PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; RASH; RECURRENT INFECTION; RELAPSE; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRUS LOAD; VIRUS MYOCARDITIS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; DRUG EFFECTS; GENETICS; GENOTYPE; HEPATITIS C, CHRONIC; HEPATITIS VIRUS; LIVER CIRRHOSIS; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; TEXAS; TIME FACTOR; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HEPATITIS VIRUSES; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TEXAS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84959337265     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.24324     Document Type: Article

References (24)

1. Lauer GM, Walker BD,. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
2. Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6: 35-47.
3. Ditah I, Ditah F, Devaki P, Ewelukwa O, Ditah C, Njei B, et al., The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 though 2010. J Hepatol 2014; 60: 691-698.
4. Forns X, García-Retortillo M, Serrano T, Feliu A, Suarez F, de la Mata M, et al., Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39: 389-396.
5. Everson GT, Terrault NA, Lok AS, Rodrigo del R, Brown RS Jr, Saab S, et al., A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis c after liver transplantation. Hepatology 2013; 57: 1752-1762.
6. Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, Ray C,. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42: 255-262.
7. Carrión JA, Martínez-Bauer E, Crespo G, Ramírez S, Pérez-del-Pulgar S, García-Valdecasas JC, et al., Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol 2009; 50: 719-728.
8. Hézode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, et al.,; for CUPIC Study Group. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890. J Hepatol 2013; 59: 434-441.
9. Rutter K, Ferlitsch A, Maieron A, Stättermayer A, Graziadei I, Dulic M, et al., Safety of triple therapy with telaprevir or boceprevir in hepatitis C patients with advanced liver disease-predictive factors for sepsis. J Hepatol 2013; 58: S30.
10. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al., Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-1887.
11. Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, et al., Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014; 384: 403-413.
12. Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, et al., Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014; 384: 414-426.
13. Forns X, Lawitz E, Zeuzem S, Gane E, Bronowicki JP, Andreone P, et al., Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014; 146: 1669-1679.
14. Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, et al., Simeprevir increases rate of sustained virological response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 2014; 146: 430-441.
15. Simeprevir (package insert). Titusville, NJ: Janssen Therapeutics; 2013
16. Sofosbuvir (package insert). Foster City, CA: Gilead Sciences; 2013
17. Stine JG, Intagliata N, Shah NL, Argo CK, Caldwell SH, Lewis JH, Northup PG,. Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis. Dig Dis Sci 2015; 60: 1031-1035.
18. Garcia-Retortillo M, Forns X,. Prevention and treatment of hepatitis C virus recurrence after liver transplantation. J Hepatol 2004; 41: 2-10.
19. Crespo G, Mariño Z, Navasa M, Forns X,. Viral hepatitis in liver transplantation. Gastroenterology 2012; 142: 1373-1383.
20. Peng CY, Chien RN, Liaw YF,. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol 2012; 57: 442-450.
21. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, et al., Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384: 1756-1765.
22. Flamm SL, Everson GT, Charlton M, Denning JM, Arterburn S. Ledipasvir/Sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study. 65th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA; November 1-5, 2014.
23. AASLD/IDSA/IAS-USA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed on June 28, 2015.
24. Curry MP, Forns X, Chung RT, et al., Pretransplant sofosbuvir and ribavirin to prevent recurrence of hcv infection after liver transplantation. Hepatology 2013; 58: 314A-315A.